Tag Archives: Spiolto® Respimat®

Boehringer Ingelheim: new data from two trials showing Spiolto® Respimat® provides significant quality of life improvements in patients with moderate to severe COPD

Posted on 29, September 2015 by

OTEMTO® 1&2 post-hoc analysis reinforces quality of life benefits provided by Spiolto® Respimat® right from the initial stage when patients first need maintenance therapy* Head-to-head ENERGITO® study shows superior lung function improvements with Spiolto® Respimat® versus LABA/ICS FDC AMSTERDAM, 29-9-2015 … Read the full press release →

Posted in Germany, Healthcare, Netherlands, Pharma & Biotech

Tagged , ,